BACKGROUND/OBJECTIVES: Fabuless (Olibra) is a commercially structured lipid emulsion, claimed to be a food ingredient that is effective for food intake and appetite reduction. The present study assessed its efficacy in a yoghurt-based mini-drink undergoing low or minimal food manufacturing (thermal and shear) processes. SUBJECTS/METHODS: Study 1: Twenty-four healthy volunteers (16 female, 8 male; age: 18 --47 years; body mass index (BMI): 17 --28 kg m À2 ) took part in a randomised, placebo-controlled, double-blind parallel crossover trial. Consumption of a minimally processed 'preload' mini-drink (containing two different doses of Fabuless or a control fat) at 2 h after breakfast was followed by appetite and mood ratings, and food intake measured in ad libitum meals at 3 and 7 h post consumption of the preload. ). A chilled, virtually unprocessed, preload breakfast mini-drink (containing minimally processed Fabuless or a control fat) was provided 5 min after a standardised breakfast, followed by appetite and mood ratings, and food intake measured in ad libitum meals at 4 and 8 h post consumption of the preload. RESULTS: The structured lipid emulsion tested had no significant effect on the primary measures of food intake or appetite. CONCLUSIONS: Even when exposed to minimal food-manufacturing conditions, Fabuless showed no efficacy on measures of appetite and food intake.
INTRODUCTION
One theoretical approach for the design of foods for weight control could be the application of technologies that deliver increased amounts of food macronutrients to the jejunum and ileum, triggering a satiety response involving glucagon-like peptide (GLP)-1 (refs 1--4) (reviewed in Maljaars et al. 5 ). A food ingredient that claims to achieve this is Fabuless (previously called Olibra and Reducal), a 42% fat emulsion formulated from oat oil and palm oil fractions currently marketed by the DMS Food Specialties BV (Delft, The Netherlands) for satiety benefits in food applications 6 in around 25 countries. 7 As recently reviewed in a meta-analysis by Appleton et al., 8 an initial series of research publications reported extraordinary effects of Fabuless on energy intake, which was reduced by up to 27% when compared with a control fat. 9 --11 Even the lowest tested concentration of 5% of this product in a yoghurt vehicle produced a remarkable 22% reduction in energy intake 4 h posttreatment. 11 All of these initial studies were performed by the same research group, but the results have never been replicated in latter work, 12 --14 even from the same group. 15 Although Diepvens et al. 12 reported an appetite-suppressing effect of this product only in a subset of young, normal-weight subjects in post-hoc analyses, and a positive effect on body-weight maintenance, the use of a parallel design and the lack of a clear supporting hypothesis makes these results difficult to interpret.
In a recently published study, we found limited evidence for functionality of Fabuless, and no efficacy after undergoing routine food production processes. 13 The intensities of homogenisation and heat used in routine food production and sterilisation processes often far exceed those applied in the 'processed' treatments in that study. We therefore questioned whether this proprietary structured lipid emulsion could be assumed efficacious in manufactured products, and concluded that this could not be assured without validated evidence in commercial products after normal processing and storage. It is important in this respect to note that Burns et al.
9 --11 did not report whether the active ingredient was added to the test yoghurts before or after processing.
The two studies reported here aimed at investigating whether the functionality of Fabuless could be demonstrated after more limited food-manufacturing processes, using two different food formulations. The first example, a yoghurt 'mini-drink' format, requires limited processing: to achieve a 6 --9 months stable product at ambient conditions, only low shear mixing and heating at 901C for 5 min is required, and this may help preserve at least part of the functionality of the unprocessed emulsion. The second example, a drink designed for storage in chilled conditions, requires even lower levels of processing, thereby further avoiding any potential detrimental effect that these processes might have on the functionality of the putative active composition.
STUDY 1---MATERIALS AND METHODS

Study design
Twenty-four healthy volunteers were recruited from the Bristol University campus through posters displayed in various departments of Bristol University. Exclusion criteria were: currently dieting to lose weight, getting up and/or having breakfast after 0900 hours regularly, skipping breakfast, lunch or dinner regularly, self-defined 'picky' eater, simultaneous involvement in other intervention studies, smoker, taking any prescription medication, and pregnant or lactating females. The exact objectives of the study were concealed in order to minimise expectancy effects. Therefore, the study was presented as investigating 'Effects of a midmorning 'shot' drink on food intake, appetite and mood'. The study protocol was approved by the relevant Human Research Ethics Committee at the University of Bristol, and participants provided written informed consent at the end of the introduction/familiarisation visit. At the very end of the study, they received a full written debriefing including an explanation of the purpose of the study.
Participants were assigned to four conditions according to a randomised double-blind, balanced-order crossover design, and were tested once a week on the same weekday where possible.
Before testing commenced, participants visited the laboratory to take part in an introduction/familiarisation session at 1400 --1530 hours, during which they practiced the appetite, satiety, mood and physical symptoms ratings (see below). Next, heights and weights of subjects were measured using a Leicester Height Measure and a Tanita Body Fat Monitor (Tanita Corporation, Tokyo, Japan) with the participant lightly clothed and without shoes. Additionally, they were given a 'Drink, Activity & Evening Snack Diary' for additional data collection, with extensive instructions. Finally, they filled in the Dutch eating behaviour questionnaire (DEBQ), 16 from which their restrained eating score was calculated. This further determined eligibility for participation according to the following final exclusion criteria for high-restrained eaters (Van Strien, personal communication, updated from Van Strien et al.
17
), intended to retain subjects more likely to be sensitive to potential physiological (vs Participants were then left with a set of instructions for the evening prior to each testing day: they were asked to eat as normally, but to limit themselves to low fibre intake, to refrain from alcohol and strenuous physical activity, and to record their food intake from 1800 hours on the evening before the first testing day, and to consume the same food before the other test days, at the same time and in the same location. Eating and drinking after 2300 hours on the evenings before test days was not allowed, with the exception of noncaloric drinks (water, coffee/tea with standardised amounts of milk/sugar), to ensure similar conditions every test day. On each of the four testing days, the following schedule was maintained: Participants arrived at the laboratory for their breakfast, which was consumed at 0830 hours. They then returned to the laboratory to consume their test drink at 1030 hours (mid-morning yoghurt-type 'shot' drink). Pleasantness ratings (paper visual analogue scales (VAS)) were recorded during the consumption of the test drink. This was followed by an ad libitum lunch at 1330 hours and an ad libitum dinner at 1730 hours, after which they returned home with a 'snack box' containing a variety of snacks for ad libitum consumption. In-between the main meals, participants carried a preprogrammed Personal Digital Assistant (PDA) (Palm Zire21, Palm Inc., Sunnyvale, CA, USA), which prompted them to fill in VAS questionnaires on the PDA, recording appetite and fatigue (described in detail in Materials and methods) at several times during the test day, while at six time points they also completed a 5-point 'physical symptoms' or 'gastro-intestinal complaints' questionnaire ( Figure 1) .
Before each ad libitum meal, participants were reminded to 'eat until you feel comfortably full---no more and no less'. The meals selected were intended to be of average liking (not disliked so that participants would eat much less than normal and possibly compensate with larger snacks in the evenings; and not overly liked so that participants would eat much more than they normally would). This was explained during their introduction/familiarisation session, as was the food they would receive, and they were asked to consider not taking part if they felt the meals were not moderately liked. Additionally, they were asked to eat the kind of food they would normally have (not going out for dinner, and so on), not to eat anything else during the testing day and to keep an activity and drinks diary on the first testing day, which they had to follow as closely as possible on each of the subsequent testing days with the explicitly explained aim of minimising inter-day variability in fluid intake and activity. Exercise and alcohol were not allowed on a testing day until later that evening, nor were additional evening meals. Snacks were allowed during the evenings of the testing days, but only from the snack boxes provided, and were recorded using the same diary. Participants were trained in VAS scoring on a PDA (see 'Measures'), and they were instructed to bring some light reading material to bridge in-laboratory waiting times, although magazines were also available. During testing, participants were confined to individual testing booths where distraction was kept to a minimum: they were visually separated, talking among participants was prohibited and mobile phones were handed to the experimenter to avoid any further distractions. For each of the laboratory-based meals, participants remained in their individual booths until all present had completed the first postmeal questionnaire on their preprogrammed PDA (15 min after starting breakfast, 30 min after starting lunch and 30 min after starting dinner). If the meal was not terminated before the PDA alarm, they were encouraged to continue eating until 'comfortably full' (see above) and then fill in their electronic questionnaire.
A schematic representation of the various activities can be found in Figure 1 .
Test foods
Breakfast. This standardised meal consisted of 45 g of Kellogg's Frosties with 115 g of Cravendale semi-skimmed milk (standardised portion size 18 ) totalling 945 kJ. T  T  T  GI  GI  GI  GI  GI GI Measurements: EI = measurement of energy intake S = questionnaire on appetite and fatigue T = questionnaire on taste and liking GI = questionnaire on gastrointestinal complaints Figure 1 . Study 1: Typical testing day schedule timeline. Participants consumed each meal (including 'shot drink') at the laboratory, leaving the testing room after all who were present had finished filling in their first post-meal electronic questionnaire. Participants were supplied with an 'evening snack box' following dinner for recording evening energy intake.
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Mid-morning yoghurt 'shot' drink (Treatment beverages). The four treatment strawberry yoghurt drinks (100 g each) were prepared from a skimmed milk base, and contained either:
2.0 g added milk fat (control shot 'low dose'; 2.2 g total fat, 2.6 g protein, 13.8 g carbohydrate, 0.5 g fibre, 368 kJ); 2.0 g added fat from 5 g Fabuless (active shot 'low dose'; nutrient composition same as control above); 3.2 g added milk fat (control shot 'high dose'; 3.4 g total fat, 2.7 g protein, 13.9 g carbohydrate, 0.5 g fibre, 414 kJ); or 3.2 g fat from the addition of 8 g Fabuless (active shot 'high dose'; nutrient composition same as above).
The added 'control' or 'active' fat was added during manufacturing of the test beverages and exposed to minimum homogenisation and pasteurisation required to achieve a 6 --9-month ambient stable product, involving only low shear mixing and heating at 90 1C for 5 min. The test beverages contained the following ingredients: yoghurt (skimmed milk, vegetable oil (palm, oat), sugar, butter, emulsifier (E472e)), water, sugar, stabiliser (pectin), acidity regulator (lactic acid), flavour and colour (carmine). They were stored at 4 --8 1C before use.
Lunch. This ad libitum meal consisted of: (1) Dinner. This ad libitum meal consisted of: (1) a large plate containing around 1000 g Sainsbury's tuna and tomato pasta bake, prepared immediately before serving in a microwave oven according to food manufacturer's guidelines; (2) five Hovis 'Best of Both' bread rolls (B250 g) (Each roll was buttered with 3 g of Flora Original margarine, and rolls were divided into four equal small portions before serving); (3) one Mr Kipling Raspberry Swiss Roll (B285 g), cut into identical slices (B1.5-cm thick); and (4) a clear jug containing 1 l of non-carbonated water. The total energy value of foods presented for subjects to select from was 13. 
Measures
The measures taken for statistical analysis were:
(1) Energy intake (kJ) during lunch, dinner, lunch þ dinner combined and from evening snacks. (2) Food intake (g) during lunch, dinner and lunch þ dinner combined. (3) Appetite-and mood-related feelings (Palm Zire PDA; 100-point VAS), measuring 'Appetite for a meal', 'Full', 'Hungry', 'Appetite for a snack', 'Thirsty', 'Satiated', 'How much you could eat', 'Energetic' and 'Drained', anchored 'not at all' and 'extremely'; (4) Physical symptoms experienced in the past hour (Palm Zire PDA; 4-point scale, labelled 'not at all', 'mild', 'moderate' and 'severe'); (5) Pleasantness ratings for various sensory aspects of the mid-morning 'shot' treatment drink (100-mm paper VAS). The questions were phrased 'Overall, how pleasant do you find the drink?' and 'How pleasant do you find the X of the drink?', with X representing 'mouthfeel/texture', 'flavour' and 'aroma'. Anchors were 'extremely unpleasant' to 'extremely pleasant'.
Statistical analysis
Primary outcomes were area under the curve (AUC) by trapezoid rule) for self-reported appetite ratings, and energy intake from ad libitum meals. The analysis was performed for AUC and also per time point using SAS (version 9.2; SAS Institute, Cary, NC, USA). Earlier studies using closely similar protocols produced a within-subject variance of about 85 mm min for AUC. Based on this variance, a confidence limit of 0.05 and a power of 0.8, 18 subjects were required for this experiment, and additional subjects were included to allow for dropouts. Data were subjected to 2 Â 2 analysis of covariance using 'the two-level factors product and dose' and the order given as factors, 'subject' and 'period' as blocks, and 'baseline measurements per visit' (t ¼ 0) as covariate. Additionally, 'active' treatments were compared with control using Fisher's Least Significant Difference test. The comparisons (two-tailed t-tests) were corrected for multiple comparisons by using a pooled error term. P-values o0.05 were considered statistically significant.
STUDY 1---RESULTS
Participant characteristics
Baseline characteristics of the 24 participants are in Table 1 . The 16 female and 8 male participants did not differ in age, BMI or dietary restraint.
Pleasantness and mood ratings, and physical symptoms No statistically significant differences in overall product pleasantness (taste, aroma and flavour), mood (energetic and drained) or adverse physical symptoms were observed between treatments (data not shown).
Appetite and satiety ratings No treatment differences were found for AUC, the key outcome measure, for any of the six self-report appetite scales. There were statistically significant differences in ratings at two isolated time points, but for different appetite scales (fullness and satiety) and not consistent for the Fabuless--control comparison, and these were not confirmed in other appetite-related VAS scales. Figure 2 shows the mean response profiles for three of the six appetite-related measures. Food and energy intake No significant effects on energy intake were observed at either the 5-or 8-g Fabuless dose level compared with control. The actual energy intakes for lunch, dinner, lunch þ dinner and evening snacks are shown in Table 2 .
STUDY 2---MATERIALS AND METHODS
Study design
The study design was similar to that of Study 1, with the following exceptions:
In order to further reduce shear and heat processing to minimal levels, the test drinks were prepared according to the guidelines for chilled yoghurt-based drinks, involving no shear stress and maximum processing temperatures of 42 1C.
The study was presented to participants as investigating 'Effects of a chilled mini-drink on satiety and energy intake'. During the information/familiarisation trial, participants were asked to indicate how much of Kellogg's Frosties and milk they would normally have for breakfast (following complaints from some participants in Study 1 that portions were either too large or too small). As Study 1 did not yield any evidence of efficacy, Study 2 adopted the approach used in previous published studies where the intervention was served at mealtimes, not between meals. Therefore, for both testing days, the following schedule was maintained: Participants arrived at the laboratory for their breakfast at 0850 hours, followed by a test drink at 900 hours. They then returned to the laboratory for their ad libitum lunch and dinner at 1300 and 1700 hours, respectively, after which they returned home with a 'snack box' containing a variety of snacks, again for ad libitum consumption. The electronic VAS questionnaires were followed by a five-point 'physical symptoms' or 'gastro-intestinal complaints' questionnaire at three time points, one immediately before each meal.
The appetite and mood ratings used in Study 1 were restricted to 'Hungry', 'Full', 'Desire to eat' and 'Preoccupation with thoughts about food', anchored 'not at all' and 'extremely'.
A schematic representation of the various activities can be found in Figure 3 .
Test foods
Breakfast. This standardised meal consisted of Kellogg's Frosties (204 kJ per 100 g) with Cravendale semi-skimmed milk (1578 kJ per 100 g), amounts of which were predetermined by the participants on an individual preference basis during the introduction/familiarisation session (see previous section), and repeated for that subject on all test days.
Test yoghurt 'shot' drink. The two treatment strawberry yoghurt drinks (100 g and 414 kJ each) contained either:
3.2 g milk fat (control shot); or 3.2 g fat from the addition of 8 g Fabuless ('active' shot).
The nutritional compositions were similar to the corresponding 8-g Fabuless treatment products in Experiment 1. In this case, however, the added 'control' or 'active' fat was added after manufacturing of the test beverages and exposed to a maximum temperature of 42 1C, thereby involving no shear mixing and only minimal heating. The test beverages contained the following ingredients: Yoghurt (skimmed milk, vegetable oil (palm and oat), sugar, butter, emulsifier (E472e)), water, sugar, flavour and colour (carmine). They were stored at 4 --8 1C before use. 
STUDY 2---RESULTS
Participant characteristics
Baseline characteristics of the 24 participants are in Table 3 . The 16 female and 8 male participants did not differ in age, BMI or dietary restraint (all P40.10)
Pleasantness and physical symptoms Pleasantness ratings for the Fabuless containing yoghurt drink were lower than for the control drink (pleasantness of texture: F(1,22) ¼ 3.8; P ¼ 0.06; pleasantness of aroma, flavour and overall: all P values o0.05). No mean treatment differences in physical symptoms were observed.
Appetite-related ratings Counter-intuitively, AUC for 'preoccupation with thoughts about food' was significantly higher for Fabuless compared with control, during the 240 --480-min posttreatment period (F(22,1) ¼ 5.7; P ¼ 0.026) as also reflected in several planned comparisons towards the end of that period, and at 420 min posttreatment (that is, 3 h post lunch) for ratings for 'hunger' (See Figure 4 for the mean response profiles for three of the four appetite-related measures). No other differences between the two conditions were observed. Food and energy intake An energy intake effect was only observed for lunch where Fabuless increased energy intake compared with control (F(1,22) ¼ 7.89; P ¼ 0.01). Similarly, on average, participants ate slightly more following Fabuless compared with control. The actual energy intakes for lunch, dinner, lunch þ dinner and evening snacks are shown in Table 4 .
DISCUSSION
The present results indicate that Fabuless has no beneficial effects on appetite or food intake when consumed in food products manufactured with limited or negligible intensities of shear and temperature. These results are largely in agreement with our previous research 13 and other recent studies reporting on the appetite-related efficacy of this commercial structured lipid emulsion. 12, 14, 15 
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Measurements: EI = measurement of energy intake S= eVAS questionnaire on appetite and satiety: "hungry", "full", "desire to eat", preoccupation with thoughts about food" T = paper questionnaire on taste and liking GI = eVAS questionnaire on gastrointestinal complaints Figure 3 . Study 2: Typical testing day schedule timeline. Participants consumed each meal ('shot drink') at the laboratory, leaving the testing room after all present had finished filling in their first post-meal electronic questionnaire. Participants were supplied with an 'evening snacking box' following dinner for recording evening energy intake. Table 3 . Study 2: Subject characteristics at baseline (mean ± s.d.)
Abbreviations: BMI, body mass index; DEBQ, Dutch eating behaviour questionnaire. Functional food ingredients that could enhance the satiating effects of foods while providing a meaningful reduction in energy intake may be highly beneficial in a weight-management context. Fabuless is marketed as such an ingredient. Initial studies performed in the late 1990s 9 --11 indicated that it reduces 24-h energy intake by up to an astonishing 30%, which would place this functional food ingredient close to anorectic drugs in terms of efficacy. 19, 20 However, in contrast, more recent studies have not supported this efficacy for appetite or food intake, and we have recently shown that Fabuless loses any apparent functionality when subjected to shear mixing and pasteurisation. 13 This suggests the putative active ingredient formulation in the Burns studies was not processed, although this is unclear from those publications. Hence, in order to determine the commercial viability of foods containing Fabuless, the two studies presented here investigated whether the functionality of this proprietary structured lipid emulsion could be demonstrated in products prepared using relatively low-impact processing procedures.
Study 1 assessed the appetite and food/energy intake suppressing effects of Fabuless undergoing limited processing in a commercial yoghurt mini-drink format. The results clearly indicate a lack of effect of this functional food ingredient on either energy intake or appetite. Both doses of Fabuless in this study---5 and 8 g (2 and 3.2 g fat)---are in a range that had been previously shown by Burns et al.
9 --11 to be effective in (what we must assume was) a non-processed yoghurt. This study therefore confirms our previous results showing no appetite-related functionality of the Fabuless emulsion after processing to produce ambient shelfstable products.
Study 2 used only the higher (8 g; 3.2 g fat) dose of Fabuless, but in a chilled mini-drink format, allowing for even lower-impact food processing than in Study 1. Counter-intuitively, the results showed an increase in absolute energy intake for lunch in the Fabuless condition, followed by further increases in feelings of 'hunger' and 'preoccupation with thoughts about food' post lunch. Significant efforts were taken in this study to try and ensure that the degree of processing applied would not impair the structural integrity of this functional food ingredient. Only fresh products with very limited shelf life might undergo milder processing, and even then it would have to be proven that the functional ingredient in a given product retains functionality throughout realistic durations and conditions of storage, temperature fluctuations and consumer use.
The lack of functional effects of Fabuless observed here is not attributable to low sample sizes or insensitivity of the measures and design, which were fully in line with recommended methods for appetite research. 21 Interestingly, the same laboratory that produced the original positive evidence for this functional food ingredient subsequently published a study where, as in the studies presented here, null effects were found. 12 Although they provide a range of alternative explanations for the failure to replicate earlier results, the strongest argument of all (that the 'active' ingredient has lost functionality) is not explored. It is possible, but not known, if different processing conditions could explain these discrepancies.
Processes such as high-shear mixing and homogenising may destabilise emulsified structures by means of coalescence or flocculation of the dispersed phase, whereas subsequent pasteurising may provide an additional destabilising risk through protein denaturisation. 22 Despite this, micrographic images of the products used in this trial (not shown here) actually indicate a somewhat finer dispersion of the lipid fraction in Fabuless after processing. However, we are not aware of any structural assessment of this product that definitively predicts integrity of its functional efficacy. Without such a test, it is difficult to predict when functionality is retained, other than by empirical clinical testing. Clearly, while it is certainly possible that different or milder processes may have less detrimental impact on efficacy, any claims for this ingredient or any products containing it can only be valid if functionality (and not just a particular structure) is known to be retained through the actual product manufacturing process and storage time and conditions. Another point that needs to be addressed is the theoretical basis for the effects found in the studies by Burns et al., 9 --11 referred to as the 'ileal brake' mechanism. This is a satiety response stimulated by the presence of slowly digested nutrients (fat in this case) in the distal small intestine, 5, 23 and involves an increase in the release of the satiety hormone GLP-1.
1 --4 Not just GLP-1, but also CCK, 24 PYY 25 and the opioid system 26 have been implicated in the ileal brake mechanism. Amounts of fat as a low as 3 g delivered directly to the ileum have been shown to trigger this mechanism, 26 suggesting that such effects of a structured food emulsion are at least plausible. Additionally, a 45-min prolonged oro-caecal transit time following the ingestion of Fabuless has been reported, 27 although we have previously challenged those findings. 13, 28 A recent report also indicates that the same product leads to an increased presence of lipids in the jejunum compared with control, 6 although the quantitative relevance and functionality in terms of satiety or food intake efficacy were not investigated, nor were GLP-1 hormone levels monitored. Furthermore, in that study Fabuless was administered at substantially higher levels (8.5 g fat) than those used in reported studies of efficacy. According to Appleton et al., 8 one study 11 has used 6 g, whereas all other studies used 5 g or less. Moreover, the limited shelf life of the treatments suggests that Fabuless may have been added unprocessed. All in all, the 'ileal brake' as an explanation for the alleged effects of this functional food ingredient remains speculative, especially given the wildly varying data on efficacy. Essential in this respect is also the fact that studies carried out after 2003 fail to show any efficacy of this product 8 irrespective of processing. Also a very recently published study failed to show a reduction in energy intake following Fabuless compared with control. 14 The observed 2003 transition point presents the possibility that either Fabuless or its production process has seen a change detrimental to the functionality reported in studies carried out before this date.
In summary, Fabuless was inactive as a functional appetitecontrol ingredient in food formats undergoing even mild food processing (a combination of no shear and maximum temperatures of only 42 1C). The results suggest that this functional food ingredient in formulations processed in ways consistent with microbiological safety and many commercial formats, is unlikely to contribute towards food intake reduction. This implies that where this product is intended to be the basis for appetite and weight management claims in commercial products, there is a need to demonstrate efficacy under actual manufacture and use conditions. We conclude that the reported efficacy of Fabuless is at best elusive, and cannot be reliably demonstrated in commercially processed foods, if at all. 
